Journal of Urology and Research

Some Biological Effects of Galactose-Specific Lectins from Prostate Tissue with Different Pathologies in Tumor Cells Model In vitro

Research Article | Open Access | Volume 9 | Issue 2

  • 1. Department of Biology, Ivane Javakhishvili Tbilisi State University, Georgia
  • 2. Department of Biology, Ivane Javakhishvili Tbilisi State University, Georgia
  • 3. A. Tsulukidze Urology National Center, Pathomorphology Laboratory 1st Clinical Hospital, Georgia
  • 4. Clinic of SJC “Modern Medical Technologies”, Georgia
  • 5. Institute of Chemical Biology, Ilia State University, Georgia
+ Show More - Show Less
Corresponding Authors
Elene Davitashvili, Department of Biology, Chair of Biochemistry, Faculty of Exact and Natural Sciences, Ivane Javakhishvili Tbilisi State University, University 0128, Tbilisi, Georgia; Tel: 995-591-270 -083

Introduction: The biological effects of cytoplasmic galactose-specific lectins fraction isolated from unaffected, as well as post-operational pathological (benign hyperplasia, BPH, high-grade intraepithelial neoplasia, HGPIN, tumor precursor, atypical adenomatous hyperplasia, AAH, and prostate adenocarcinoma, PC) prostate tissues were studied on tumor cell lines (MEC1 lymphocytes cell line and Human prostate PC3-cell line)

Methods and Results: Cytosolic galactose-specific lectin fractions from prostate tissue with different diagnosis were purified by affinity chromatography. The lectin effects were studied on cell viability by MTT reduction method and on apoptosis by flow cytometry method. All testified lectin fractions, except from AAH tissue, markedly reduced also the cell viability in MEC1 and PC3 cell lines and fraction isolated from HGPIN and PC tissues in time dependent manner increased apoptosis in MEC1 line lymphocytes.

Conclusions: Cytosolic galactose-specific lectins fractions depend on the form of glandular tissue disease and also on the type of cell (lymphocytes, PC3, used in the research). Our findings suggest that lectins isolated from HGPIN and PC tissues can have defensive anti-tumor properties in tumors cell - MEC1 line lymphocytes and prostate PC3 cell line.


Apoptosis, Cells survival viability, Gland diseases, Prostate galactose-specific lectins


AAH: Atypical Adenomatous Hyperplasia; BPH: Benign Prostate Hyperplasia; HGPIN: High-Grade Intraepithelial Neoplasia; PC: prostate adenocarcinoma; Post-op: Post Operation

Cite this article

Davitashvili E, Burjanadze G, Dachanidze N, Koshoridze M, Koshoridze N, et al. (2022) Some Biological Effects of Galactose-Specific Lectins from Prostate Tissue with Different Pathologies in Tumor Cells Model In vitro. J Urol Res 9(2): 1135.


It has been recognized that the structure of cell surface glycans can change under different physiological and pathological conditions. In cancer biology, aberrant glycosylation changes, resulting in expression of altered carbohydrate determinants on many glycoproteins and glycolipids has been known as one of the most important changes related to tumor malignancy [1]. Some of these significant interactions related to carbohydrates are mediated through binding to specific proteins interacting with carbohydrate determinants. Specific proteins selectively binding [2,3].

Prostate cancer is the second leading cause of cancer death in males after lung cancer [4]. In prostate cancer galectins have been implicated in many cellular processes such as proliferation, apoptosis, migration and invasion [5,6] and are considered as potential prognostic markers and potential therapeutic targets for this type of pathology [7]. The prostate tissue could have different grades of pathologies which in turn could lead to the formation of prostate adenocarcinoma (PC) [8]. These forms are as follows: benign hyperplasia (BPH), high-grade intraepithelial neoplasia (HGPIN tumour precursor) [9], atypical adenomatous hyperplasia (AAH) and PC [8]. Each of them is characterized with specific histology and molecular signature [5].

In our previous study, we have shown that affinity purified cytosolic galactose-specific lectins fractions from normal and pathological prostate tissue samples are characterized with different protein composition and they expressed different effects on cell viability and apoptosis of healthy blood lymphocytes in vitro [10].

The present study is focused on cytoplasm galactose-specific lectins effects on cell viability, and apoptosis in the pathological cells on the example of MEC1 cell line lymphocytes and Human prostate cancer PC3 cell line. MEC1 cell line was established from EBV-seropositive patient’s Chronic Lymphocytic Leukemia cells and iswidely used as a model for CLL pathogenesis. We have expanded the source of galactose-specific lectins and carried out experiments on lectins purified from prostatic tissues with the following diagnosis: BPH, HGPIN, AAH, PC as well as from unaffected tissue (norm).


Editorial Policies and Ethical Consideration

The ethical approval of the study as long as the guidelines followed to carry out the study was also obtained from Georgian National Center for disease control and public health (Institutional Review Board Letter 2021-069). Approval for the use of the tissues was obtained from the local ethical committee at A. Tsulukidze Urology National Modern Center, Pathomorphology Laboratory at the 1st Clinical Hospital and Clinic of SJC “Modern Medical Technologies”, and the patients’ written consent. However, through dissemination process, we made sure that the patients’ data protection system is firmly implemented and that no leakage of personal data or the results of the diagnosis, prognosis etc. into public domain takes place. This was insured through the implementation of modern guidelines of ethics and data protection as planned in this application. The study design was approved by the internal review board of the institution. The scientific research was carried out at Ivane Javakhishvili Tbilisi State University, Faculty of Exact and Natural Sciences, Department of Biology, in tight coordination of chairs of Biochemistry and Immunology/Microbiology.

Patient’s characteristics and samples

Prostate post-operational tissue samples were obtained from: A. Tsulukidze Urology National Modern Center, Pathomorphology Laboratory at the 1st Clinical Hospital and Clinic of SJC “Modern Medical Technologies”. Human prostate tissue samples were obtained from patients undergoing open trans-abdominal prostatectomies for benign prostate hyperplasia and transurethral resection of the prostate (TURP). The numbers of testified tissues were: 1. Unaffected (N, normal) tissue isolated after cytoprostatectomies, n=7 (age 47-68 years); 2. benign prostatic hyperplasia (BPH) with LGPIN diagnosis, n=35 (age 55-70 years); 3. with HGPIN diagnosis n=17 (age 50-68 years); 4. with AAH diagnosis n=22 (age 50-75 years) and 5. PC diagnosis n=11 (age 54-67 years). All patients were otherwise healthy. After removal of tissue specimens’ pathological conditions were confirmed by histopathology. The diagnoses were drawn according to the histopathology diagnostic criteria [11], by examining of needle biopsies (before the operation) and paraffinembedded slices (after an operation). The cells in slices with AAH diagnosis had clear cytoplasm, lack malignant nuclear features, prominent nucleoli occur in 21-25% of cases. The nuclear size and anisonucleosis are the main features of cells in slices with LGPIN diagnosis.

Prostate epithelial and stroma were not separated from each other, and the whole tissue was used for lectin purification


Affinity chromatography sorbent-agarose with immobilized the NAcGal (Cat.N.A2787), WST1-reagent (4-[3-(4-Iodophenyl)- 2-(4-nitro-phenyl)-2H-5-tetrazolio]-1,3-benzene sulfonate) (Cat.N.5015944001), Histopaque1077, Propidium iodide (PI,P4864), RNaseA (89836) were purchased from Sigma-Aldrich, Dorset, UK), RPMI-1640, Fetal bovine serum, Protein Assay Kit (Sigma, USA) were purchased from Sigma Chemical, CO.,USA. Commercial lectins (PNA (Arachis hypogaea (peanut agglutinin), SNA (Sambucus nigra,), HPA (Helix pomatia), PHA (Phaseolus vulgaris-phytohemagglutinin), SBA (soybean agglutinin), Con A (Canavaliaensiformis,jak-bean) and WGA (Triticum vulgaris, wheat germ agglutinin) were purchased from Sigma-Aldrich.

Prostate galactose-specific lectins isolation procedure

Galactose-specific lectins were isolated from the cytosolic fractions (S3 -fraction) of human prostate post-operational tissue with different diagnoses. Prostate tissues were homogenized in 0.32 M sucrose and centrifuged at 1000× g for 10 min. The supernatant (S1) was collected and centrifuged at 17,000×g for 55min, resulting in the S2 supernatant and the P2 pellet (crude mitochondrial fraction). S2 was centrifuged at 100,000×g for 1 to generate the P3 pellet (microsomal fraction) and S3 supernatant (cytosolic fraction).

For lectin purification these cytosolic fractions were saturated by ammonium sulphate (to 80% saturation), the mixtures allowed to stand overnight at 4°C. The precipitates were collected by centrifugation at 12,000 g for 20 min, redissolved in a minimal volume of phosphate buffer saline (PBS), pH 7.4, dialysed overnight against the PBS at 4°C, and then centrifuged at 12,000 g for 15 min. Obtained supernatants were examined for hemagglutination activity and sugar specificity, and were used for the purification of galactose-specific lectins by affinity chromatography (agarose with immobilized the NAcGal (“Sigma-Aldrich”, Cat.N.A2787). The galactose-specific lectins fractions were eluted with 0.2 M galactose, 0.2M lactose and 0.05 M glycine-HCl buffer (pH 3.0) at 0.5 ml/min flow rate and immediately neutralised. Lectins fractions were dialysed and concentrated by the filter (AmiconUltra-15 Centrifugal Filter10 kDa, UFC901008). The yield of galactose-specific lectin fraction from 1 g of post-operation tissue was approximately 70-100 mkg of protein.

Peripheral Blood Mononuclear Cells (PBMCs) isolation procedure

PBMCs were isolated from the blood of healthy (35-50 year) men. PBMCs were isolated in Histopaque1077 gradient (density: 1.076–1.078 g/mL) (Sigma-Aldrich, Dorset, UK), and cell concentration was adjusted as required in RPMI-1640 medium supplemented with 10% fetal bovine serum (both Sigma-Aldrich) [12]. Cells number was counted in a hemocytometer and the concentration of cells adjusted to the required number for each experiment.

Cell Culture

PC-3 cells line (Sigma-Aldrich) were maintained in the RPMI 1640 containing 10% FBS, 100 units/ml penicillin, 100 µg/ ml streptomycin, L-glutamine and sodium pyruvate. Cells were incubated in humidified atmosphere (37°C, 5% CO2 ).

MEC1-cells line (donated by the University of Westminster, UK) [13] were cultured in RPMI 1640 supplemented with 10% heat-inactivated FBS,100 units/ml penicillin, and 100 µg/ ml streptomycin in humidified incubator at 37°C and 5% CO2 . Cells grew in suspension, forming small and large clumps with round shape. The morphology of growing cells was evaluated on cytocentrifuge smears stained with May-Grunewald Giemsa (MGG). We counted the number of cells per 24 hours by hemocytometer (Sigma).

Cell viability experiments

The effect of lectins on the cell survival was studied in model experiments by MTT reduction method [13] using the WST1-reagent(4-[3-(4-Iodophenyl)-2-(4-nitro-phenyl)-2H-5- tetrazolio]-1,3-benzenesulfonate) (“Sigma Aldrich”5015944001). The experiments were carried out on cancer cells - leukemiaMEC1- linelymphocytes and prostate cancer PC3-line cells culture). The concentration of cytosolic galectins comprised 5 μg/10x106 lymphocytes/well (200 µl incubation area) and 10x105 PC3 cells/well. Cell suspensions were incubated with purified lectins fractions from different sources in 96-well tissue culture plates. Microtiter plates were kept for 1 h at 37°C, after which the medium was removed, and the culture washed with PBS. To each microtiter well the FBS-RPMI10% was added, followed by the 10µl WST-1. Plates were incubated in an incubator at 370 C for 30 min. Results have been read twice: immediately after WST-1 addition and second time 30 min (incubation time) later. The absorbance was measured by ELISA reader Multiscan GO Microplate Reader (Thermo Scientific, USA) at 430 nm (WST-1) and with 630 nm as a reference read-out. A blank with WST-1 alone was measured and subtracted from all values.

Apoptotic Cell Cycle Analysis (Apoptosis assay)

The effects of cytosol galactose-specific lectins fractions isolated from PC and HGPIN diagnosed tissue cells were also studied on lymphocytes apoptosis by flow cytometry method. Lectin concentration comprised 5 μg/10x106 cells (200 µl incubation area), the incubation time was 1 h, and cells were washed with PBS. Cell cycle analysis was carried out at 0 sec, 24 h, 48 h, 72 h. The apoptotic cells numbers were counted (only viable cells have been assessed). DNA content of propidium iodide (PI,P4864) stained cells was measured by flow cytometry and separated into phases of the cell cycle based on the PI fluorescence [14,15]. PI intercalates into double-stranded nucleic acids, binds to DNA stoichiometrically and its fluorescence is enhanced upon binding. The enzyme RNaseA was used to degrade double-stranded RNA. Cell concentration was adjusted to 1x106 cells/ml for each sample, centrifuged at 600g for 5 min, washed in PBS, the pellets were well vortexed, fixed in ice-cold 70% ethanol added drop-by-drop to the vortexes cells and maintained overnight at 4°C. Cells were then stained with a fluorochrome solution containing 20 μg/ml PI in PBS, 50 μg/ ml RNase A (“Sigma-Aldrich”, 89836) for 30 min at 37°C and analyzed by FACScan flow cytometer (Becton & Dickinson). The DNA histogram showed the cell cycle distribution of the non-apoptotic cells. The apoptotic cells should be observed as a distinct sub-G1 peak of the hypo diploid DNA.

Sugar-specificity control experiments

In hemagglutination assays, cell viability and apoptosis experiments, control samples contained 0.1M galactose in a final concentration.

Statistical Analysis

The data of cell viability experiments were analyzed by oneway analysis of variances (ANOVA) with factor – lectin source (BPH, HGPIN, AAH and PC). The data of apoptosis were analyzed by two-way ANOVA with factors: time of incubation and lectin source (HGPIN, and PC). Planned comparisons were carried out with student t-test. All tests were two-tailed unless otherwise stated, and P value less than or equal to 0.05 was taken as significant. All significant results are reported.



The effect of galactose-specific lectins fractions from prostate tissue on leukemic MEC1-line lymphocytes viability in model experiments

One-Way ANOVA revealed that the effect of the factor of lectin source on the leukemia MEC1-line lymphocytes viability was significant (F5, 29=18.19, P<0.001) (Figure 1). Cytosolic lectin fractions from all sources except AAH diagnosis significantly reduced the viability of leukemia MEC1-line lymphocytes (Normal cytosolic lectins vs Control cells T=6.53, P≤ 0.001; BPH vs. Control cellsT= 12.48 P≤ 0.0001; BPH vs. normal cytosolic lectins T= 6.32 P≤ 0.001; BPH vs. AAH T= 14.56P≤ 0.001; HPGIN vs Control cells T=2.96 P= 0.018; HPGIN vs AAH T = 3.83 P = 0.005; PC lectins vs Control cells T = 17.10 P≤ 0.001 PC lectins vs normal cytosolic lectins T= 7.64 P≤ 0.001; PC lectins vs AAH lectins T=19.22 P≤ 0.001, for all comparisons DF=8). No other differences were significant.

Thus, the cytosolic galactose-binding lectin fractions from prostatic tissues with different pathologies have different effects on cell viability depending on the lectin’s fractions source (prostatic tissues diagnoses).

The effect of cytoplasm galactose-specific lectins fractions  isolated from normal and diseased prostate tissue on leukemia MEC1- line lymphocytes viability. The data are mean ± SEM. **- p<0.001 as  compared to controls. Other comparison results are provided in the  manuscript.

Figure 1 The effect of cytoplasm galactose-specific lectins fractions isolated from normal and diseased prostate tissue on leukemia MEC1- line lymphocytes viability. The data are mean ± SEM. **- p<0.001 as compared to controls. Other comparison results are provided in the manuscript.

The effect of commercially available plant lectins on lymphocytes viability

Considering that lectins effect is exerted in relation of lectins with the specific carbohydrate determinant of glycoconjugates, the effect was compared with the effect of some commercially available plant lectines (“Sigma-Aldrich”) with different carbohydrate specific lectins.

The lectins– PNA (Arachis hypogaea (peanut agglutinin),βgalactose-), SNA (Sambucus nigra, sialic acid-, α-NAcNANA(2-)6) Gal/NAcGal), HPA (Helix pomatia, βD-galactose), PHA (Phaseolus vulgaris-phytohemagglutinin, bi- and tri-antenal N-glycan-), SBA (soybean agglutinin,NAcGal), Con A (Canavaliaensiformis,jakbean, mannose-, D-manopiranose-, D-glucopiranoside) and WGA (Triticum vulgaris, wheat germ agglutinin, NAcGlu-) were also used (Figure 2). The lectins effect on MEC1 cell line was compared with effect on normal lymphocytes (healthy blood).

Among the galactose-specific lectins the PNA and HPA (but not SBA lectin) significantly reduced the cell viability in both, normal [F(16,46)=16,171] and MEC1-line lymphocytes [F(10,21)=49,8, (p < 0.001)]. No effect was revealed in MEC1 line lymphocytes viability by SNA and Con A lectins. Con A decreased only normal lymphocytes surviving and WGA reduced in both, normal and MEC1–line lymphocytes viability (Figure 2).


Figure 2 Influence of commercial different carbohydrate-specific lectins on viability of normal blood and leukemia MEC1-line lymphocytes. Note: The data are mean ± SEM. *p < 0.05, **p < 0.001.

The effect of galactose-specific lectins fractions from prostate tissue on prostate PC3-cells viability

One-way ANOVA revealed that the effect of the factor–lectin source is significant on the viability of the PC-3 cells (F5,29 =9.83, P≤ 0.001). In general, all lectins decreased the PC-3 cell viability. The strongest effect is observed for lectins from BPH tissue (BPH vs Control cells T=24.23 P≤ 0.001 DF = 8; BPH vs lectins from normal tissue T = 2.71 P = 0.027 P<0.05 DF = 8; BPH vs HGPIN T = 8.35 P≤ 0.001 DF = 8 and BPH vs AAH T= 10.31 P≤ 0.0001 DF = 8). All other lectins from prostatic tissue with different diagnosis significantly decrease the cell viability of PC-3 cells as compared to control conditions (lectins from normal tissue vs Control cells T= 2.86 P = 0.021 DF = 8; lectins from HGPIN diagnosis as compared to control cells T= 4.46 P≤ 0.001 DF = 8; lectins from AAH diagnosis as compared to control cells T= 9.93 P≤ 0.001 DF = 8 and lectins from PC cells as compared to control cells T= 4.00 P≤ 0.001 P 0.004 DF = 8) (Figure 3).

The effect of cytoplasm lectins fraction on prostate cancer  PC3-line cells viability. Note: The data are mean ± healthy and SEM.  *- p<0,05, **- p<0.001 as compared to controls. Other comparison  results are provided in the manuscript.

Figure 3 The effect of cytoplasm lectins fraction on prostate cancer PC3-line cells viability. Note: The data are mean ± healthy and SEM. *- p<0,05, **- p<0.001 as compared to controls. Other comparison results are provided in the manuscript.

Among the commercial lectins with different carbohydratespecificity the SBA (NAcGal), PNA (β-galactose), PHA (N-glycan) and ConA (mannose) significantly decreased the PC3 cells viability (p<0,001, [F(10,21)=49,8], no effect had SNA (sialic acid-specific lectin) (Figure 4) as in MEC1 lymphocytes viability (Figure 2).

Commercial lectins effect on viability of PC3-cells. Con A –  mannose-spec., PHA – N-glycan-sp., PNA- ?-galactose-sp., SNA- sialic  acid-spec.,SBA – NAcGal-spec. lectins.Note: The data are mean ± SEM.  *p < 0.05, **p < 0.001.

Figure 4 Commercial lectins effect on viability of PC3-cells. Con A – mannose-spec., PHA – N-glycan-sp., PNA- β-galactose-sp., SNA- sialic acid-spec.,SBA – NAcGal-spec. lectins.Note: The data are mean ± SEM. *p < 0.05, **p < 0.001.

The effect of galactose-specific lectins fraction on cell apoptosis

Based on previous studied of the effect of galactose-specific lectins from prostate tissue with different pathology on the normal blood lymphocytes [10], were able to study the role of cytosolic galactose-specific lectins fraction on apoptosis from PC and HGPIN tissue lectins. The effect of lectins fraction on the cell cycle was studied in vitro in MEC1 line lymphocytes

Two way ANOVA revealed that the effects of factors lectins source and time were significant (F1,23=2221.61 P≤ 0.001 and F3,23=247.81, P≤ 0.001) and their interaction is also significant ( F3,23=247.19, P≤ 0.001).

In control cells significant decrease is observed at 48h as compared 0h (T= 3.36 P = 0.028 DF = 4) and 72h time points (T = 6.72 P = 0.003 DF = 4) (Figure 5).

Influence of cytosolic galactose-specific lectins from tissue  with the different diagnosis on peripheral blood leukemic MEC1- line lymphocytes apoptosis by flow cytometry technique.Sub-G1  (apoptotic) cells number - %. The data are mean ± SEM. **p < 0.001, as  compared to initial time point. Other comparison results are provided  in the manuscript.

Figure 5 Influence of cytosolic galactose-specific lectins from tissue with the different diagnosis on peripheral blood leukemic MEC1- line lymphocytes apoptosis by flow cytometry technique.Sub-G1 (apoptotic) cells number - %. The data are mean ± SEM. **p < 0.001, as compared to initial time point. Other comparison results are provided in the manuscript.

Cytosolic galactose specific lectin fraction from prostatic tissue with HPGIN diagnosis significantly decreases the apoptosis of leukemic MEC-1 line lymphocytes at 48h (48h vs 0 h T = 7,63 P= 0.002 DF = 4; 48h vs 24h T= 10.01 P= 0.001 DF = 4) followed by sharp increase at 72 h (72h vs 48h T= 27.36 P≤ 0.001 DF = 4).

Incubation of leukemia MEC1-line lymphocytes with cytosolic galactose binding lectins from prostatic tissue with PC diagnosis leads to gradual increase of apoptosis and starting from 24h the levels are significantly higher as compared to 0h value (24hvs0h T= 24.39 P≤ 0.001; 48h vs 0h T = 30.75P≤ 0.001; 72h vs 0h T = 45.05 P≤ 0.001 for all comparisons DF= 4). The highest rate of apoptosis is observed at 72h significantly exceeding the corresponding values at 24h and 48h ( T= 11.81 P≤ 0.001 DF = 4; T= 14.88 P≤ 0.001 DF = 4 respectively) (Figure 5).



In the presented study discussed the effects of cytoplasmic galectins fractions isolated from normal and diseased human prostate tissue with different diagnosis (BPH, HGPIN, AAH and PC) on cell viability and apoptosis in tumor cell cultures (leukemia MEC1-line lymphocytes and prostate PC3).

Unlike normal healthy lymphocytes [10], a different effect is manifested in the case of tumor cells. The effect also varies depending on the cell type. The same lectin affects differently on leukemia MEC1-line lymphocytes and PC3 cell viability. All lectins from normal as well as from diseased prostate tissue except from AAH diagnosis are decreasing viability of leukemic MEC1-line lymphocytes, and all forms of lectin fractions decreased the PC3 cells viability.

In all cases of experiments, the effects of cytosolic galectin fractions on the cell’s viability are conditioned by a specific binding with cells membrane surface glycoconjugates. Lectins effects are mediated by carbohydrate-binding domains since the addition of galactose in the incubation medium completely abolished these effects. So, the change of lectin biological function is depending on the glycoconjugate’s carbohydrate structure. Glycosylation is one of the most common co- or posttranslational modifications. Malignant transformation is associated with abnormal glycosylation, changes the carbohydrate structure of the membrane and becomes the primary cause of metastasis [6,16]. The differences in glycosylation of proteins within the diseased prostate tissue, such as BPH and prostatic carcinoma comparing with normal tissues [16], were revealed. The carcinoma tissue intensifies the expression of proteins with the galactose residues [6,16,17].

Presumably the β-galactose-/N-acetyl-galactosamine/ lactose-containing glycoconutates are exposed on the normal and leukemic MEC1-line lymphocytes and PC-3-line cells membrane surface. The use of the exogenous (plant) lectins with different carbohydrate-specificity revealed also exhibited of mannose-/Nacetylglucosamine-containing glycoconjugates too (Figure 2,4). However, the β-galactose-specific lectins (as from prostate tissue as testified plant galactose-specific lectins) act differently on the viability of different types of cells. This effect is due to the fact that lectins influence on the cell viability and apoptosis through different pathways and some being more effective than others in specific cell lines [18].

The galactose-specific lectins expression varies according to prostate state pathologies [6,17]. The composition of cytosolic galactose-speciic lectins in isolated fractions (norm, BPH, HGPIN, AAH, PC) is different [10] and may contribute to various steps in tumor progression. Despite this galectins from PC and HGPIN (tumor precursor) diagnosed prostate tissue are increasing apoptosis as in normal lymphocytes [14], as in leukemic MEC1- line lymphocytes. We suggest that galectins from PC and HGPIN in both cases involved a similar mechanism of apoptosis.


There was studied the biological properties of cytosolic galactose-specific lectins, isolated from unaffected (norm) tissue (after cytoprostatectomies) and diseased prostate tissue with different diagnoses (BPH/LGPIN, HGPIN, AAH and PC) in vitro system.

We conclude that the effect of cytosolic galactose-specific lectins fractions 1) depends on the form of glandular tissue disease and also on the type of cell (lymphocytes, PC3, used in the research), 2) is likely to depend significantly on the cell surface glycoconjugate’s nature and structure and 3) the effect of cytosolic galactose-specific lectins fractions isolated from HGPIN and PC tissues can have defensive and anti-tumor properties in tumors cell – MEC1 line lymphocytes and prostate PC3 cell line.


The authors confirm contribution to the paper as follows: data collection and preparation of the figures - George Burjanadze, Natali Dachanidze and Marine Koshoridze. Investigation of lectins’ effect on cell cycle - Tamar Tsertsvadze and Nunu Mitskevich. Supplying the prostate post-operational tissue for further observations and tissue analyzes – Guram Karazanashvili (Surgeon) and Omar Tsintsadze. Statistical analyzes, co-writing and revision of the manuscript - Nana Koshoridze and Revaz Solomonia. Supervision, writing of the manuscript, revision and preparation for the submission, corresponding author - Elene Davitashvili.


1. Haltiwanger R, Lowe J. Role of glycosylation in development. Annu Rev Biochem. 2004; 73: 491- 537.

2. Varki A, Cummings R, Esko J, Freeze H, Stanley P, Bertozzi C, et al. Essentials of Glycobiology. 2nd ED by Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. 2008.

3. Ghazarian H, Idoni B, Oppenheimer S. A glycobiology review: carbohydrates, lectins and implications in cancer therapeutics. Acta Histochem. 2011; 113: 236-247.

4. Jemal Ah, Bray Fr, Melissa M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.

5. Solis D, Bovin N, Davis A, Jiménez-Barbero J, Romero A, Roy R, et al. A guide into glycosciences: How chemistry, biochemistry and biology cooperate to crack the sugar code. Biochim Biophys Acta. 2015; 1850: 186-235.

6. Compagno D, Gentilini LD, Jaworski FM, Pérez IG, Contrufo G, Laderach DJ. Glycans and galectins in prostate cancer biology, angiogenesis and metastasis. Glycobiology. 2014; 24: 899-906.

7. Martínez-Bosch N, Rodriguez-Vida A, Juanpere N, Lloreta J, Rovira A, Albanell J, et al. Galectins in prostate and bladder cancer: tumourigenic roles and clinical opportunities. Nat Rev Urol. 2019; 6: 433-445

8. Zynger DL, Yang X. High-grade Prostatic Intraepithelial Neoplasia of the Prostate: The Precursor Lesion of Prostate Cancer. Int J Clin Exp Pathol. 2009; 2: 327-338.

9. Arenas M, Romo E, de Gaspar I, de Bethencourt F, Sánchez-Chapado M, Fraile B, et al. A lectin histochemistry comparative study in human normal prostate, benign prostatic hyperplasia and prostatic carcinoma. Glycoconj J. 1999; 16: 375-382.

10.Davitashvili E, Burjanadze G, Koshoridze M, Koshoridze N, Tsertsvadze T, Mitskevich N, et al. Galactose specific lectins from prostate tissue with different pathologies: biochemical and cellular studies. Mol Biol Rep. 2022; 49: 443-450.

11.Tadrous JP (Ed.). In: Diagnostic Criteria Handbook in Histopathology. A surgical Pathology. 2007.

12.Dube H, Bertozzi CR. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov. 2005; 4: 477-488.

13.Stockert JC , Blázquez-Castro A, Cañete M, Horobin RW, Villanueva Á. MTT assay for cell viability: Intracellular localization of the formazan product is in lipid droplets. Acta Histochem. 2012; 114: 785-796.

14.Hofbauer SW, Piñón JD, Brachtl G, Haginger L, Wang W, Jöhrer K, et al. Modifying Akt Signaling in B-Cell Chronic Lymphocytic Leukemia Cells. Cancer Res. 2010; 70: 7336.

15.Krishan A. Rapid flow cytofluorometric analysis of cell cycle by propidium iodide staining. J Cell Biol. 1975; 66: 188.

16.Rillahan CD, Paulson JC. Glycan microarrays for decoding the glycome. Annu Rev Biochem. 2011; 80: 797-823.

17.Chan F, Choi H, Ho S. Analysis of glycoconjugate patterns of normal and hormone-induced dysplastic Noble rat prostates, and an androgenindependent Noble rat prostate tumor, by lectin histochemistry and protein blotting. Prostate. 2001; 46: 21-32.

18.Yau T, Dan X, Ng Ch, Tzi B. Lectins with potencial for anti-cancer therapy. Molecules. 2015; 20: 3791-810.

19.Hsu DK, Yang RY Liu F. Galectins in apoptosis. Methods Enzymol. 2006; 417: 256.

20.Laderach DJ, Gentilini L, Jaworski FM, Compagno D. Galectins as New Prognostic Markers and Potential Therapeutic Targets for Advanced Prostate Cancers. Prostate Cancer. 2013; 2013: 519436.

21.Liu F, Rabinovich G. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005; 5: 29-41. 22.Crissman HA, Steinkamp JA. Rapid simultaneous measurement of DNA, protein and cell volume in single cells from large mammalian cell populations. J Cell Biol. 1973; 59: 766

Received : 13 Oct 2022
Accepted : 28 Nov 2022
Published : 05 Dec 2022
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X